Suchergebnisse - "Ma, Liangming"

PubPharm (20)

1

The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset : A nationally representative, prospective, multicentre, observational study

enthalten in: Annals of hematology | 2024

von Fu, H. | Cai, X. | Cui, L. | +82

2

Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease

enthalten in: Blood science (Baltimore, Md.) | 2024

von Zhao, J. | Yang, H. | Ge, J. | +9

3

Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome : A prospective multicenter clinical cohort study

enthalten in: Chinese medical journal | 2024

von Cao, Y. | Wang, M. | Wang, F. | +38

4

Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center

enthalten in: Hematology (Amsterdam, Netherlands) | 2023

von Lian, Y. | Ti, J. | Ma, L. | +2

5

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19

enthalten in: Blood science (Baltimore, Md.) | 2023

von Lian, Y. | Gao, Z. | Ti, J. | +3

6

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib : A single-arm, open-label, phase 2, multicenter study

enthalten in: American journal of hematology | 2023

von Zhang, Y. | Zhou, H. | Duan, M. | +21

7

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib : A single-arm, open-label, phase 2, multicenter study

enthalten in: American journal of hematology | 2023

von Zhang, Y. | Zhang, Q. | Liu, Q. | +15

8

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group

enthalten in: Heliyon | 2023

von Ai, H. | Chao, N. | Rizzieri, D. | +71

9

Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy

enthalten in: Anti-cancer drugs | 2023

von Gao, Z. | Lian, Y. | Ti, J. | +2

10

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib : A single‐arm, open‐label, phase 2, multicenter study

enthalten in: American Journal of Hematology | 2023

von Zhang, Y. | Zhang, Q. | Liu, Q. | +15